127 175

Cited 2 times in

At least one cyclic teriparatide administration can be helpful to delay initial onset of a new osteoporotic vertebral compression fracture

Authors
 Kyung Soo Suk  ;  Hwan Mo Lee  ;  Seong Hwan Moon  ;  Hee June Kim  ;  Hak Sun Kim  ;  Jin Oh Park  ;  Byung Ho Lee 
Citation
 Yonsei Medical Journal, Vol.55(6) : 1576-1583, 2014 
Journal Title
 Yonsei Medical Journal 
ISSN
 0513-5796 
Issue Date
2014
Abstract
PURPOSE: Teriparatide markedly increases bone formation and strength, while reducing the incidence of new-onset osteoporotic vertebral compression fractures (OVCFs). In some countries, expenses for teriparatide use are covered by medical insurance for up to 6 months; however, the national medical insurance of the authors' country does not cover these expenses. This retrospective cohort study compared the therapeutic effects of teriparatide on the initial onset of a new OVCF after treatment of osteoporosis and/or related OVCFs with regard to therapeutic durations of longer than 3 months (LT3M) or shorter than 3 months (ST3M). MATERIALS AND METHODS: From May 2007 to February 2012, 404 patients who were prescribed and administered teriparatide and who could be followed-up for longer than 12 months were enrolled. They were divided into two groups depending on teriparatide duration: LT3M (n=132) and ST3M (n=272). RESULTS: The group with the teriparatide duration of LT3M showed significantly less development of an initial OVCF within 1 year (p=0.004, chi-square). Duration of teriparatide use, body mass index, pre-teriparatide lowest spinal bone mineral density, and severity of osteoporosis significantly affected multiple regression analysis results (p<0.05). Survival analysis of first new-onset OVCFs demonstrated a significantly better survival rate for the LT3M group (log rank, p=0.005). Also, the ST3M group showed a higher odds ratio of 54.00 for development of an initial OVCF during follow-up than the LT3M group (Mantel-Haenzel common odds ratio, p=0.006). CONCLUSION: At least one cyclic teriparatide administration is recommended to provide a protective effect against the initial onset of a new OVCF for up to one year after therapy.
Files in This Item:
T201404481.pdf Download
DOI
10.3349/ymj.2014.55.6.1576
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Orthopedic Surgery (정형외과학교실) > 1. Journal Papers
Yonsei Authors
김학선(Kim, Hak Sun) ORCID logo https://orcid.org/0000-0002-8330-4688
문성환(Moon, Seong Hwan)
박진오(Park, Jin Oh)
석경수(Suk, Kyung Soo) ORCID logo https://orcid.org/0000-0003-0633-2658
이환모(Lee, Hwan Mo) ORCID logo https://orcid.org/0000-0002-5405-3832
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/138374
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse